Pharmaceutical industry news

NCT06487481: Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Study type: INTERVENTIONAL. Phase: PHASE1.

NCT06357377: A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

Study type: INTERVENTIONAL. Phase: PHASE1.

NCT06215118: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Study type: INTERVENTIONAL. Phase: PHASE1.

NCT05854498: Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Study type: INTERVENTIONAL. Phase: PHASE2.

NCT05800873: Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Study type: INTERVENTIONAL. Phase: PHASE1.

NCT05648500: A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Study type: INTERVENTIONAL. Phase: PHASE3.

NCT05646212: Integrating Treatment for Mental Disorders in Methadone Clinics in Ukraine

Study type: INTERVENTIONAL. Phase: NA.

NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Study type: INTERVENTIONAL. Phase: PHASE3.

NCT05593003: [Trial of device that is not approved or cleared by the U.S. FDA]

Study type: . Phase: .

NCT04969315: TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

NCT03602092: Observational Registry Data on GIST Patients

Study type: OBSERVATIONAL. Phase: .

NCT03233347: Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Study type: INTERVENTIONAL. Phase: PHASE2.

NCT02974621: Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Study type: INTERVENTIONAL. Phase: PHASE2.

NCT01920737: A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Study type: INTERVENTIONAL. Phase: PHASE2.

NCT00501800: Genetic Epidemiology of Ovarian Aging

Study type: OBSERVATIONAL. Phase: .

Government Should Increase Transparency of Medicare Drug Rebate, Not Undermine Pharmaceutical Innovation

Lonza invests in Bend with new spray-drying pharmaceutical facility

A Single Dose of Pharmaceutical LSD Cut Anxiety Scores Five Points Below Placebo in Phase 3 Trial

FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace

ETFs Investing in SciVision Biotech Inc. Stocks

[Click e-Stock] "SK Biopharmaceuticals: No Adverse Reactions in Over 1,200 Clinical Patients...Target Price Maintained at 160,000 Won"

Antibody Responses in Health and Disease: un encuentro internacional para avanzar en el conocimiento de la inmunidad

As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety

#CONVEGNO [21.09] Fattori di rischio e differenti scenari nella MASLD. Una sfida quotidiana per l'internista - Gratuito con crediti ECM

Pharma Manufacturing: eXoZymes picks Curia as commercial-scale manufacturing partner

All Eyes (Should Be) On Patient Centricity in Clinical Research

Cooper Green adds enrollment specialists at UAB St. Vincent’s Birmingham, UAB St. Vincent’s East

The Relationship Between GLP-1 Use and Trust in Pharmaceutical Companies

First Community Credit Union executive to lead 2026 Heart Walk and citywide push for CPR readiness

Turning a potent greenhouse gas into a valuable pharmaceutical building block using light

PharmaCyte Biotech 2026: Revenue $0 Net income ($5.79M), EPS ($0.54) — 10-Q Summary

Takeda Pharmaceutical Company: Upcoming launches and data readouts signal a major inflection point for growth and innovation

PMCB 10-Q Filings - PharmaCyte Biotech, Inc. SEC 10-Q

About 200 Long COVID patients joined a drug trial. BioVie will discuss results Tuesday.

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

IceCure Medical Exhibits ProSense Cryoablation for Breast Cancer at EUSOBI 2026 in Maastricht

Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Takeda Pharmaceutical Company: Major launches and data readouts drive a pivotal strategic shift, with new leadership at the helm

Novo Nordisk Enters Rebrand | PharmExec

Avoiding a sticky situation: how cells stop messenger RNAs from clumping together

FDA Recalls and Warnings: Zicam Nasal Swabs Recalled, Foreign Pills Found in Trazodone Bottles

WuXi AppTec Hires Sander Lurie on Health Issues

Experimental treatment improves blood flow in PH-ILD patients’ lungs

Russian tuberculosis vaccine enters Phase 3 trials

Psychedelics Are Wall Street’s Next Trip. Why This Biotech Stock Is Already Up 200%.

With just $6K left, Nymox Pharmaceutical (NYMXF) discloses doubt it can keep operating

Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger?

Experts urge FDA to set clear safety and access standards for psychedelic drugs

PDS Biotech Raises $11.3 Million in Initial PIPE Led by Patrick Soon-Shiong

Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger?

US FDA To Hold Psychedelic Drug Hearing Amid Trump Push: What It Means For Depression, PTSD

New FDA Hepatic Impairment Guidance: What It Means for Your Next Dedicated Study

Is Krystal Biotech (KRYS) Cheap On Its Cantor Conference Spotlight?

BTIG raises Cullinan Oncology stock price target on trial data

OWKIN Highlights AI-Driven Forecasting for Phase 3 Clinical Trial Outcomes

Major updates for Apple’s software platforms are now available

Siri AI, a profoundly more capable and personal assistant, is here

GenSci registers Phase I trial of four-target retinal fusion protein across three indications

Apple’s new child safety features now available

Lilly cans early experimental obesity drug after ‘high bar’ not met